Financial Data and Key Metrics Changes - Total revenue for Q2 was RMB 379 million, a decrease of 7% year over year, primarily due to a decline in medical service providers subscribing to information services [15] - Aesthetic treatment service revenues reached RMB 144 million, an increase of 426% year over year, exceeding guidance [15] - Net loss attributable to the company was RMB 36 million, compared to a net income of RMB 18.9 million in the same period last year [19] - Non-GAAP net loss was RMB 30.5 million, compared to a non-GAAP net income of RMB 22.2 million in the same period of 2024 [19] - Basic and diluted losses per ADS were RMB 0.35, compared to earnings of RMB 0.18 in the same period last year [19] Business Line Data and Key Metrics Changes - Revenue from aesthetics center business reached RMB 144 million, marking it as the largest revenue segment for the first time [4] - Aesthetic treatment services revenue increased by 46% quarter over quarter and 426% year over year [5] - Total number of verified treatment visits surpassed 67,400 in Q2, up 24% quarter over quarter and 381% year over year [7] - The overall repeat purchase rate for the aesthetic center business exceeded 60% [7] Market Data and Key Metrics Changes - The light medical aesthetic market in China is expected to reach around RMB 26 billion by 2030, with a penetration rate forecasted to reach 30% [30] - The company aims to achieve a market share of roughly 25% in the light medical aesthetic sector [30] Company Strategy and Development Direction - The company plans to open around 10 aesthetic centers in the third quarter, targeting a total of 50 centers by year-end [11] - The focus is on expanding in both first-tier and core second-tier cities, enhancing accessibility to medical aesthetic services [11] - The company is committed to optimizing user experience and operational efficiency to strengthen its competitive edge [13] Management Comments on Operating Environment and Future Outlook - Management remains optimistic about the growth potential of China's medical aesthetic market, citing a current penetration rate below 5% [30] - The company expects aesthetic treatment service revenues to be between RMB 150 million and RMB 170 million in the upcoming quarter, representing a significant increase from the same period in 2024 [20] - The company emphasizes the importance of sustainable low-cost customer acquisition and a diversified upstream supply chain [31] Other Important Information - The company has maintained a robust cash position with cash and cash equivalents totaling RMB 98.6 million as of June 30, 2025 [20] - The gross profit margin for aesthetic treatment services expanded by around five percentage points sequentially [8] Q&A Session Summary Question: Expansion plan for C and I payment and franchise model - The company aims to grow the number of centers to 50 by the end of this year, with plans for more than 10 openings in the second half [24] - Long-term, the target is to achieve 1,000 centers within eight to ten years, with franchising being a future focus [25][26] Question: Growth potential of the Chinese medical aesthetics market - Management is optimistic about the market, with substantial growth potential indicated by a low current penetration rate [30] - The company plans to focus on three core capabilities to maintain its competitive edge [31] Question: Outlook for customer acquisition cost and marketing expenses - The average customer acquisition cost remains low, with over 70% of new customers coming from referrals [34] - The company plans to enhance brand visibility through localized marketing initiatives [34] Question: Recruitment of doctors and reliance on center managers - There is a solid base for recruiting doctors, with many moving from public hospitals to the medical aesthetic sector [40] - The company operates on a model that reduces reliance on center managers, improving operational efficiency [42] Question: Differentiation in product strategy - The product strategy focuses on anti-aging treatments, ensuring consistency and overall cost-effectiveness across the portfolio [46] - The company aims to optimize its product portfolio based on market demand and competitive trends [48] Question: Updates on the POP business - The POP business remains a key pillar of profitability, with plans to promote synergies between POP and aesthetic center businesses [50]

Financial Performance - New Oxygen (SY.US) reported Q2 revenue of 378.7 million RMB, a year-on-year decrease of 7.0%, exceeding market expectations [1] - The company posted a net loss of 36 million RMB, compared to a net profit of 18.9 million RMB in the same period last year [1] - The loss per ADS was 0.35 RMB, down from a profit of 0.18 RMB per ADS in the previous year [1] Revenue Breakdown - Revenue from beauty treatment services was 144.4 million RMB, a significant year-on-year increase of 426.1% [1] - Revenue from information and booking services was 135.2 million RMB, a year-on-year decrease of 35.6% [1] - Sales from medical products and maintenance services were 76 million RMB, down 28.1% year-on-year [1] - Other service income decreased by 64.0% to 23.2 million RMB [1] User Engagement - The total transaction volume facilitated by New Oxygen's platform for medical beauty was 303.9 million RMB, compared to 427.8 million RMB in the same period of 2024 [1] - The number of active users exceeded 100,400, a significant increase from approximately 16,000 in the previous year [2] - The company operates 29 fully operational brand aesthetic centers across nine major cities, with 25 centers achieving positive monthly operating cash flow [2] Future Guidance - For Q3 2025, New Oxygen expects revenue from beauty treatment services to be between 150 million and 170 million RMB, representing a year-on-year growth of 230.5% to 274.6% [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Raily Aesthetic Medicine International Holdings Limited 瑞麗醫美國際控股有限公司 （於開曼群島註冊成立的有限公司） 1 （股份代號：2135） 終止合約安排 茲提述招股章程及年報。 誠如招股章程及年報所披露，杭州貝麗菲爾的業務營運涉及在中國從事醫療美容 服務業務（「受限制業務」）。由於當時生效的中國適用法律法規限制外商投資於受 限制業務，本集團於2019年1月就杭州貝麗菲爾採用了合約安排，通過合約安排使 本集團得以有效控制杭州貝麗菲爾並可獲得杭州貝麗菲爾所產生的所有經濟利益。 由於杭州貝麗菲爾決定將策略重點放在醫療美容器械產品的銷售業務上並計劃申 請醫療器械經營許可證，而本公司已根據中國法律法規終止杭州貝麗菲爾的醫療 美容服務業務並註銷杭州貝麗菲爾的醫療執業許可證，因此對於受限制業務的外 資所有權限制不再適用於杭州貝麗菲爾。董事會謹此宣佈，合約安排的 ...

Group 1 - The medical beauty sector increased by 0.43% on August 15, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 3696.77, up 0.83%, while the Shenzhen Component Index closed at 11634.67, up 1.6% [1] - Key stocks in the medical beauty sector showed varied performance, with *ST Meigu closing at 3.20, up 1.59%, and Aimeike down 0.37% at 181.89 [1] Group 2 - On the same day, the medical beauty sector experienced a net outflow of 1.09 billion yuan from institutional investors, while retail investors saw a net inflow of 69.52 million yuan [2] - The data indicates a mixed sentiment among different types of investors in the medical beauty sector [2]

Core Viewpoint - The article summarizes important announcements from various listed companies in the Shanghai and Shenzhen stock markets, providing insights for investors regarding significant corporate actions and financial results. Major Events - Cambrian: The company announced that recent online information regarding large orders and revenue forecasts is misleading and not true [4] - China Shipbuilding: The company has applied for voluntary delisting following a merger with China Shipbuilding Industry [5][6] - Kanda New Materials: The company plans to acquire 51% of Chengdu Zhongke Huamei for 275 million yuan to expand in the semiconductor integrated circuit sector [7] - Aimeike: A major arbitration case involving its subsidiary REGEN has been initiated, with a claim of approximately 1.6 billion yuan [8] - China Evergrande: A hearing regarding the company's liquidation is scheduled for September 16, with shares continuing to be suspended [9] - *ST Suwu: The company's stock price fell below 1 yuan, risking delisting if it remains below this threshold for 20 consecutive trading days [10] - Foton Motor: The company has identified tax payment issues amounting to approximately 28.83 million yuan for the years 2022-2024 [11][12] - Wolong Electric: The company has submitted an application for H-share issuance and listing in Hong Kong [13] - Dayuan Pump Industry: The company clarified that its liquid cooling business is part of its original operations, with first-quarter sales of approximately 1.6 million yuan [14] - Gansu Energy: The Jinhe Coal Mine has resumed production after passing safety inspections [15] - Chipsea Technology: The company plans to issue H-shares to enhance its international strategy [16] Financial Performance - China Telecom: Reported a net profit of 23.017 billion yuan for the first half of 2025, a year-on-year increase of 5.5% [17] - JD Group: Achieved a revenue of 356.7 billion yuan in Q2 2025, a year-on-year growth of 22.4% [19] - Chuanjinno: Reported a net profit of 177 million yuan for the first half of 2025, a significant increase of 166.51% [20] - Darentang: Achieved a net profit of 1.928 billion yuan for the first half of 2025, a year-on-year increase of 193.08% [21] - Baodi Mining: Reported a net profit of 61.592 million yuan for the first half of 2025, a decline of 40.11% [22] - Bailong Oriental: Achieved a net profit of 390 million yuan for the first half of 2025, a year-on-year increase of 67.53% [23] - Dunhuang Seed Industry: Reported a net profit of 54.454 million yuan for the first half of 2025, a year-on-year increase of 73.43% [24] - Huarui Precision: Achieved a net profit of 85.4597 million yuan for the first half of 2025, a year-on-year increase of 18.80% [25] - Chongqing Beer: Reported a net profit of 865 million yuan for the first half of 2025, a decline of 4.03% [26] - Heertai: Achieved a net profit of 354 million yuan for the first half of 2025, a year-on-year increase of 78.65% [27] Shareholding Changes - Junshi Biosciences: Major shareholder Shanghai Tanying plans to reduce its stake by up to 2% [28] - Tibet Tourism: Major shareholder Lvtou Group plans to reduce its stake by up to 0.97% [29] Strategic Partnerships - Shanying International: The company has signed strategic investment cooperation agreements with Yunyin Technology and Proton Technology to enhance industrial applications in the paper and packaging sectors [30]

Core Viewpoint - The article discusses the tightening regulations on medical advertising in response to the increasing prevalence of misleading advertisements disguised as health information, particularly in the context of the internet's rapid development [1][3]. Summary by Sections Medical Advertising Regulation Challenges - Medical advertising has become more complex with the rise of the internet, leading to a blurring of lines between health education and advertising [1]. - In the first half of the year, regulatory authorities handled 1,666 cases of illegal medical advertising, imposing fines totaling 12.78 million yuan [1]. Introduction of the Recognition Guidelines - The State Administration for Market Regulation, in collaboration with the National Health Commission and the National Administration of Traditional Chinese Medicine, has developed the "Medical Advertising Recognition Guidelines" to clarify what constitutes medical advertising [3][4]. - The guidelines emphasize the importance of legitimate advertising entities and aim to address issues related to unqualified "black hospitals" and "black doctors" misleading the public [3]. Key Changes in the Guidelines - The guidelines prohibit any entity or individual, except legally established medical institutions, from publishing medical advertisements [4]. - The previous ambiguous definitions regarding promotional activities and health education have been removed, tightening the criteria for what constitutes advertising [4]. - The guidelines specify that linking health education content to medical services or products constitutes disguised advertising [4]. Focus on Internet Platforms - The rise of internet platforms has increased the volume of medical advertising, making it difficult for consumers to distinguish between advertising and educational content [6]. - Recent policies in Beijing aim to enhance compliance and promote legal awareness regarding medical advertising on digital platforms [6]. Collaborative Regulatory Efforts - The guidelines call for a coordinated approach among various regulatory bodies to effectively manage medical advertising [8]. - Local market supervision bureaus are collaborating with health and law enforcement departments to create a comprehensive regulatory network [8]. - A tiered regulatory approach is being implemented to avoid one-size-fits-all enforcement, allowing for leniency in minor violations [8].

风险提示：股市有风险，投资需谨慎。 公司境外控股子公司阿卡邦2025年半年度报告显示，其净利润为2877万元，同比下降13.29%。营业收 入4.52亿元，同比下降3.27%。利润下滑主要由于自营店铺增加导致商场费用上升，以及汇率变化影 响。 截至2025年8月14日15时，朗姿股份股价报17.21元，较前一交易日下跌0.54元，跌幅3.04%。当日开盘 价为17.75元，最高触及17.78元，最低下探至17.20元，成交量为94110手，成交金额达1.65亿元。 8月14日主力资金净流出4059.90万元，占流通市值0.93%。近五个交易日累计净流出7755.09万元，占流 通市值1.77%。 朗姿股份主营业务涵盖服装设计、生产和销售，同时涉及医疗美容服务等业务领域。公司旗下拥有多个 自主品牌，并通过境外子公司阿卡邦开展业务。 来源:金融界 ...

Group 1 - Tongda Power achieved a net profit of 42.64 million yuan in the first half of 2025, a year-on-year increase of 32.49% [1] - The company reported an operating income of 971 million yuan, up 22.07% year-on-year [1] - Basic earnings per share were 0.26 yuan [1] Group 2 - Hengshen New Materials reported a net loss of 36.70 million yuan in the first half of 2025, compared to a loss of 10.37 million yuan in the same period last year [2][3] - The company's operating income decreased by 24.84% to 1.22 billion yuan [2] Group 3 - Yiming Pharmaceutical's net profit was 37.56 million yuan, down 5.27% year-on-year [4] - The company experienced an 11.52% decline in operating income, totaling 311 million yuan [4] - Basic earnings per share were 0.20 yuan [4] Group 4 - Wangsu Technology achieved a net profit of 37.30 million yuan, a year-on-year increase of 25.33% [5] - The company's operating income was 2.35 billion yuan, up 2.19% year-on-year [5] - Basic earnings per share were 0.1524 yuan [5] Group 5 - Alloy Investment reported a net profit of 4.58 million yuan, a year-on-year increase of 44.12% [6] - The company achieved an operating income of 164 million yuan, up 73.46% year-on-year [6] - Basic earnings per share were 0.0119 yuan [6] Group 6 - Yifan Pharmaceutical's net profit was 30.40 million yuan, a year-on-year increase of 19.91% [8] - The company's operating income was 2.635 billion yuan, up 0.11% year-on-year [8] - Basic earnings per share were 0.25 yuan [8] Group 7 - Guoyao Yizhi reported a net profit of 66.60 million yuan, a year-on-year decrease of 10.43% [9] - The company's operating income was 36.797 billion yuan, down 2.62% year-on-year [9] - Basic earnings per share were 1.20 yuan [9] Group 8 - Hanjia Design expects a net profit of 15 to 16.5 million yuan, a year-on-year increase of 303.20% to 343.52% [10] - The company anticipates a net profit excluding non-recurring gains and losses of 14.5 to 17.5 million yuan, a year-on-year increase of 867.05% to 1067.13% [10] Group 9 - Gansu Energy Chemical announced the resumption of production at its Jinhe Coal Mine after passing safety inspections [16] Group 10 - Chuanjin Nuo reported a net profit of 177 million yuan, a year-on-year increase of 166.51% [18] - The company's operating income was 1.744 billion yuan, up 27.91% year-on-year [18] - Basic earnings per share were 0.6457 yuan [18] Group 11 - Yachuang Electronics achieved a net profit of 40.82 million yuan, a year-on-year increase of 1.47% [19] - The company's operating income was 2.847 billion yuan, up 125.74% year-on-year [19] - Basic earnings per share were 0.29 yuan [19] Group 12 - Yiheda reported a net profit of 282 million yuan, a year-on-year increase of 26.49% [14] - The company's operating income was 1.461 billion yuan, up 18.70% year-on-year [14] - Basic earnings per share were 0.44 yuan [14] Group 13 - Hatao Technology reported a net profit of 38 million yuan, a year-on-year increase of 233.08% [33] - The company's operating income was 1.475 billion yuan, up 1.12% year-on-year [33] - Basic earnings per share were 0.18 yuan [33] Group 14 - Anlu Technology announced that shareholders plan to reduce their holdings by no more than 3.25% of the company's shares [35] Group 15 - Baolidi reported a net profit of 63.81 million yuan, a year-on-year increase of 15.19% [36] - The company's operating income was 676 million yuan, up 1.47% year-on-year [36] - Basic earnings per share were 0.36 yuan [36] Group 16 - Harta Technology reported a net profit of 33.50 million yuan, a year-on-year increase of 55.61% [38] - The company's operating income was 335 million yuan, up 22.54% year-on-year [38] - Basic earnings per share were 0.0698 yuan [38] Group 17 - Huaxia Biological's controlling shareholder received a loan commitment of up to 250 million yuan from China Merchants Bank [58]

从资金流向上来看，当日医疗美容板块主力资金净流出1.01亿元，游资资金净流入4340.59万元，散户资 金净流入5715.55万元。医疗美容板块个股资金流向见下表： 证券之星消息，8月14日医疗美容板块较上一交易日下跌1.86%，华熙生物领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.15 | 0.00% | 10.44万 | 3292.65万 | | 832982 | 锦波生物 | 296.75 | -1.57% | 1.06万 | 3.15 Z | | 300896 | 爱美客 | 182.56 | -1.85% | 3.60万 | 6.66 Z | | 688363 | 华熙生物 | 52.50 | -2.05% | 4.12万 | 2.19亿 | | 代码 | | | 名称 | | | | | --- | --- | ...

Core Viewpoint - The joint release of the "Medical Advertising Recognition Guidelines" by the State Administration for Market Regulation, the National Health Commission, and the National Administration of Traditional Chinese Medicine aims to combat misleading medical advertisements and clarify the responsibilities of medical institutions in advertising [1][2]. Group 1: Regulatory Measures - The guidelines strictly limit the publication of medical advertisements to legally established medical institutions, prohibiting any individual or entity from publishing medical advertisements independently or through others [2]. - The guidelines address the issue of misleading advertisements disguised as medical information or health education, specifying which forms of information disclosure and health education do not constitute advertisements, while also listing specific scenarios where such disclosures are misused [2]. - The guidelines establish institutional arrangements for the transfer of leads and situation reporting between market regulation departments and health authorities to effectively address the chaos in medical advertising [2]. Group 2: Enforcement Actions - In the first half of 2025, market regulation departments across the country handled 1,666 cases of illegal medical advertising, with fines totaling 12.78 million yuan [1]. - The State Administration for Market Regulation has publicly exposed 30 typical cases of illegal advertisements in three batches, covering various sectors including medical beauty and medical devices, creating a strong deterrent effect [1]. - The guidelines are part of a broader effort to enhance collaboration between market regulation departments and health authorities, establishing a regular mechanism for joint assessment and enforcement [2].